Biotech companies at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

76 biotech companies are at ESGCT 2026 — 134 presentations on the program. Most represented: Solid Biosciences (6 on the program), uniQure (5 on the program), VectorY Therapeutics (5 on the program). 35 of them have their own page in this guide. As of Oct 16, 2026.

All 450 organizations at ESGCT 2026 →

Showing 1–10 of 76 organizations

Organization	ESGCT 2026 Attendance
Solid Biosciences Charlestown, Massachusetts
solidbio.com Biotech Develops AAV gene therapies for neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy, plus capsid and manufacturing technology.	Poster Wed Oct 28 1:30pm–3:30pm Impact of Genome Size and Sequence Composition on AAV Vector Genome Integrity AAVs / non integrative vectors Poster Wed Oct 28 1:30pm–3:30pm SGT-003 gene therapy restores DAPC stability and improves muscle integrity in Duchenne muscular dystrophy Cardiovascular & Muscular diseases Poster Wed Oct 28 1:30pm–3:30pm Transcriptomic profiling identifies G2/M cell cycle modulation as a strategy to enhance rAAV production Manufacturing Poster Thu Oct 29 2:00pm–4:00pm Boosting rAAV yield and quality in HEK293 cells through multi‑mechanism strategies Manufacturing Poster Thu Oct 29 2:00pm–4:00pm Development and implementation of a high yield and scalable manufacturing process for Adeno-associated virus (AAV) production Manufacturing Poster Thu Oct 29 2:00pm–4:00pm Mechanism of improved POLARIS-101TM capsid transduction AAVs / non integrative vectors Poster Thu Oct 29 2:00pm–4:00pm Successful Polaris‑101TM transduction of multiple tissues after depletion of preexisting antibodies using a novel IgG-degrading enzyme Immune responses to GT
uniQure Amsterdam, Netherlands
uniqure.com Biotech Develops AAV gene therapies for genetic and neurological diseases, including AMT-130 for Huntington's disease, and developed the hemophilia B therapy Hemgenix.	Poster Wed Oct 28 1:30pm–3:30pm BBB-Penetrant AAV Capsid Discovery via Transferrin Receptor Targeting for Preclinical CNS Gene Therapy AAVs / non integrative vectors Poster Wed Oct 28 1:30pm–3:30pm Direct targeting of the liver and lung with a knockdown and replace strategy for alpha-1 antitrypsin deficiency Metabolic diseases Poster Wed Oct 28 1:30pm–3:30pm Dual targeting of somatic instability and HTT in Huntington’s disease: an optimized AAV gene therapy strategy CNS & sensory Poster Wed Oct 28 1:30pm–3:30pm Silencing at the source: reducing nuclear HTT transcripts and RNA foci in the R6/1 HD mouse model using AAV-delivered miRNA AAVs / non integrative vectors Poster Thu Oct 29 2:00pm–4:00pm Systemic delivery of AAV gene therapy with dual targeting of HTT and somatic instability using a blood–brain barrier-penetrant capsid rescues survival in R6/2 Huntington's disease model. CNS & sensory
VectorY Therapeutics Amsterdam, Netherlands
vectorytx.com Biotech Develops AAV-delivered vectorized antibody therapies for neurodegenerative diseases such as ALS and Huntington's disease.	Poster Wed Oct 28 1:30pm–3:30pm A scalable and quality driven insect cell–baculovirus manufacturing platform enables 1000L production of VTx-002, an AAV based vectorized antibody for ALS Manufacturing Poster Wed Oct 28 1:30pm–3:30pm From Single-Cell Analysis to Clinical Dose: Setting the Therapeutic Threshold for VTx-002 in ALS Motor Neurons CNS & sensory Poster Wed Oct 28 1:30pm–3:30pm Leveraging Analytical Characterization to Drive Scalable GMP Manufacturing and Regulatory Advancement of VTx-002, an AAV-based vectorized antibody for ALS Manufacturing Poster Wed Oct 28 1:30pm–3:30pm No DRG toxicity in AAV5-vectorized antibody therapy after intracisternal magna administration in nonhuman primates CNS & sensory Poster Wed Oct 28 1:30pm–3:30pm Validation of HTT CAG50 iPSC‑Derived Neurons to Support Drug Discovery in Huntington’s Disease Disease Models Rare and inherited disease
AviadoBio London, UK
aviadobio.com Biotech Develops AAV gene therapies for neurodegenerative diseases such as frontotemporal dementia, including AAV-delivered microRNA to silence MAPT.	Poster Wed Oct 28 1:30pm–3:30pm Leveraging the vMiXTM miRNA platform to silence alpha-synuclein (SNCA) as a therapeutic strategy for synucleinopathies CNS & sensory Poster Thu Oct 29 2:00pm–4:00pm Evaluation of rationally designed synthetic promoters for expression in neurons and glial cells AAVs / non integrative vectors Poster Thu Oct 29 2:00pm–4:00pm Silencing of MAPT via AVB-406 in human iPSC-derived neurons: A translational framework for neurodegenerative disease. AAVs / non integrative vectors Talk Thu Oct 29 5:15pm–6:00pm AVB-406: An intravenous AAV-miRNA achieving sustained MAPT knockdown for the treatment of Alzheimer's disease and other tauopathies SESSION 9a: CNS & sensory II Vectors and delivery (AAV, lentiviral, LNP)RNA and oligonucleotide therapies
Integra Therapeutics Barcelona, Spain
integra-tx.com Biotech Develops FiCAT, a gene writing platform combining CRISPR-Cas targeting with an engineered piggyBac transposase to insert large payloads, for CAR-T and in vivo therapies.	Poster Wed Oct 28 1:30pm–3:30pm FiCAT gene writing platform for liver-directed in vivo gene therapy AAVs / non integrative vectors Poster Wed Oct 28 1:30pm–3:30pm Programmable genomic insertion of kilobase sized payloads via FiCAT 2.0 gene writing platform Gene Editing Poster Thu Oct 29 2:00pm–4:00pm Development of viral-free FiCAT gene writing platform for liver-directed in vivo application Gene Editing Poster Thu Oct 29 2:00pm–4:00pm FiCAT: Precise Genomic Integration for Advanced CAR-T Production Non viral delivery
Addition Therapeutics
additiontx.com Biotech Develops PRINT, an all-RNA platform delivered by lipid nanoparticles that uses an R2 retrotransposase to insert therapeutic genes durably.	Talk Thu Oct 29 10:00am–10:30am Precise, RNA-mediated insertion of transgenes using an R2 retrotransposase yields stable, durable, and therapeutic hepatic protein expression, from mice to NHPs SESSION 7b: Genome editing II Gene and epigenome editingVectors and delivery (AAV, lentiviral, LNP) Poster Thu Oct 29 2:00pm–4:00pm Durable In Vivo Expression of Engineered Incretin Agonists Using PRINT Metabolic diseases Poster Thu Oct 29 2:00pm–4:00pm Preclinical proof-of-concept of treatment for Fabry disease via precise RNA-mediated insertion of a GLA transgene Disease Models Rare and inherited diseaseGene and epigenome editing
Alaya.bio New York, New York
alaya.bio Biotech Develops in vivo CAR-T therapies that use targeted polymeric nanoparticles to reprogram T cells inside the patient; R&D in Villejuif, France.	Poster Wed Oct 28 1:30pm–3:30pm An integrated manufacturing platform for lentiviral vectors-based nanoparticle enabling accelerated clinical translation for in situ gene delivery therapies Manufacturing Poster Wed Oct 28 1:30pm–3:30pm In vivo polymeric gene delivery platform for targeted cell reprogramming in hematological malignancies Immunotherapy and CAR T cells Poster Thu Oct 29 2:00pm–4:00pm Lentivector engineering with polymer surface modification for targeted in vivo CAR-T cell therapy Lentiviral vectors / Integrative vectors
CPTx Planegg, Germany
cptx.bio Biotech Develops immune-quiet single-stranded DNA delivered by targeted lipid nanoparticles to generate CAR-T cells inside the body.	Poster Wed Oct 28 1:30pm–3:30pm ssDNA-tLNPs enable multiplex in vivo CAR-T engineering across fibrotic and oncologic disease models Immunotherapy and CAR T cells Poster Thu Oct 29 2:00pm–4:00pm Advanced characterization of ssDNA-loaded targeted lipid nanoparticles for in vivo CAR T cell therapy Immunotherapy and CAR T cells Talk Fri Oct 30 12:30pm–1:00pm Targeted immune-silent ssDNA-tLNP delivery enables in vivo CAR-T generation and eradication of disseminated tumors SESSION 12d: Non-viral vectors/Nanotechnology and RNA therapeutics II Vectors and delivery (AAV, lentiviral, LNP)Cell therapies and CAR-T
Dyno Therapeutics Watertown, Massachusetts
dynotx.com Biotech Uses AI to design AAV capsids with better delivery to tissues such as the brain and muscle, and partners with gene therapy developers.	Poster Wed Oct 28 1:30pm–3:30pm AI-enabled single-shot design of an ALPL-targeting AAV capsid with exceptional cross-species CNS and muscular delivery efficiency following systemic administration CNS & sensory Poster Thu Oct 29 2:00pm–4:00pm AI-guided engineering of dual-mechanism AAV capsids enhances muscle delivery, reduces CNS tropism, and confers cross-species translation in NHP and mouse AAVs / non integrative vectors Poster Thu Oct 29 2:00pm–4:00pm Systematic iterative AI-enabled engineering of antibody-evasive AAV capsids across diverse CNS- and muscle-targeting mechanisms AAVs / non integrative vectors
MeiraGTx New York, NY
meiragtx.com Biotech Clinical-stage gene therapy company with AAV programs, riboswitch-controlled gene expression and its own vector manufacturing.	Poster Wed Oct 28 1:30pm–3:30pm Denaturing size exclusion chromatography-MS for characterisation of AAV and assessment of CQAs AAVs / non integrative vectors Poster Thu Oct 29 2:00pm–4:00pm A commercial in-vitro biological activity potency assay for AAV-AQP1 treatment of Xerostomia AAVs / non integrative vectors Poster Thu Oct 29 2:00pm–4:00pm AAV-NRF2 rescues RPE cell function and viability in human IPSC-derived and mouse models of oxidative stress CNS & sensory